Charles River Laboratories International (CRL)
(Delayed Data from NYSE)
$231.24 USD
-1.40 (-0.60%)
Updated May 23, 2022 04:00 PM ET
3-Hold of 5 3
B Value A Growth D Momentum B VGM
Income Statements
Fiscal Year end for Charles River Laboratories International, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/21 | 12/31/20 | 12/31/19 | 12/31/18 | 12/31/17 | |
---|---|---|---|---|---|
Sales | 3,540 | 2,924 | 2,621 | 2,266 | 1,858 |
Cost Of Goods | 2,206 | 1,850 | 1,663 | 1,426 | 1,155 |
Gross Profit | 1,335 | 1,074 | 958 | 840 | 702 |
Selling & Adminstrative & Depr. & Amort Expenses | 745 | 641 | 607 | 509 | 415 |
Income After Depreciation & Amortization | 590 | 433 | 351 | 331 | 287 |
Non-Operating Income | -35 | 101 | 14 | 14 | 39 |
Interest Expense | 74 | 86 | 61 | 64 | 30 |
Pretax Income | 481 | 447 | 304 | 282 | 297 |
Income Taxes | 82 | 82 | 50 | 54 | 171 |
Minority Interest | 8 | 1 | 2 | 2 | 2 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 399 | 365 | 254 | 227 | 126 |
Extras & Discontinued Operations | 0 | 0 | 0 | 2 | 0 |
Net Income | 391 | 364 | 252 | 226 | 123 |
Depreciation Footnote | 12/31/21 | 12/31/20 | 12/31/19 | 12/31/18 | 12/31/17 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 855 | 668 | 549 | 493 | 419 |
Depreciation & Amortization (Cash Flow) | 266 | 235 | 198 | 162 | 131 |
Income After Depreciation & Amortization | 590 | 433 | 351 | 331 | 287 |
Earnings Per Share Data | 12/31/21 | 12/31/20 | 12/31/19 | 12/31/18 | 12/31/17 |
---|---|---|---|---|---|
Average Shares | 51.43 | 50.61 | 49.69 | 49.02 | 48.56 |
Diluted EPS Before Non-Recurring Items | 10.32 | 8.13 | 6.73 | 6.03 | 5.27 |
Diluted Net EPS | 7.60 | 7.20 | 5.07 | 4.62 | 2.54 |
Fiscal Year end for Charles River Laboratories International, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/22 | 12/31/21 | 9/30/21 | 6/30/21 | 3/31/21 | |
---|---|---|---|---|---|
Sales | 913.93 | 905.05 | 895.94 | 914.61 | 824.57 |
Cost Of Goods | 577.11 | 557.94 | 558.71 | 572.59 | 516.29 |
Gross Profit | 336.82 | 347.11 | 337.23 | 342.02 | 308.28 |
SG&A, R&D, and Dept/Amort Expenses | 188.04 | 174.30 | 181.42 | 204.47 | 184.57 |
Income After SG&A, R&D, and Dept/Amort Expenses | 148.78 | 172.81 | 155.81 | 137.55 | 123.71 |
Non-Operating Income | -28.50 | 2.38 | -16.08 | 6.14 | -27.68 |
Interest Expense | 9.43 | 11.55 | 16.46 | 16.19 | 29.72 |
Pretax Income | 110.85 | 163.64 | 123.27 | 127.50 | 66.30 |
Income Taxes | 15.62 | 23.82 | 18.11 | 37.58 | 2.37 |
Minority Interest | 2.20 | 2.25 | 1.73 | 1.47 | 2.41 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 95.23 | 139.83 | 105.16 | 89.92 | 63.94 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income | 93.02 | 137.58 | 103.43 | 88.45 | 61.53 |
Earnings Per Share Data | 3/31/22 | 12/31/21 | 9/30/21 | 6/30/21 | 3/31/21 |
---|---|---|---|---|---|
Average Shares | 51.33 | 51.56 | 51.56 | 51.33 | 51.08 |
Diluted EPS Before Non-Recurring Items | 2.75 | 2.49 | 2.70 | 2.61 | 2.53 |
Diluted Net EPS | 1.81 | 2.67 | 2.01 | 1.72 | 1.20 |